Free Trial
NASDAQ:INDP

Indaptus Therapeutics (INDP) Stock Price, News & Analysis

Indaptus Therapeutics logo
$0.80 -0.02 (-1.85%)
As of 03:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Indaptus Therapeutics Stock (NASDAQ:INDP)

Key Stats

Today's Range
$0.74
$0.88
50-Day Range
$0.75
$0.97
52-Week Range
$0.70
$3.10
Volume
1.55 million shs
Average Volume
123,520 shs
Market Capitalization
$11.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Buy

Company Overview

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Remove Ads

Indaptus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

INDP MarketRank™: 

Indaptus Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 288th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Indaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Indaptus Therapeutics has received no research coverage in the past 90 days.

  • Read more about Indaptus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Indaptus Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Indaptus Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Indaptus Therapeutics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Indaptus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.51% of the float of Indaptus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Indaptus Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Indaptus Therapeutics has recently decreased by 25.86%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Indaptus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Indaptus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.51% of the float of Indaptus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Indaptus Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Indaptus Therapeutics has recently decreased by 25.86%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Indaptus Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Indaptus Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for INDP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Indaptus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    29.50% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.06% of the stock of Indaptus Therapeutics is held by institutions.

  • Read more about Indaptus Therapeutics' insider trading history.
Receive INDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INDP Stock News Headlines

Indaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last year
A brutally honest economic warning for 2025 (see proof)
New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....
Indaptus Therapeutics (INDP) to Release Earnings on Wednesday
See More Headlines

INDP Stock Analysis - Frequently Asked Questions

Indaptus Therapeutics' stock was trading at $0.8421 at the beginning of the year. Since then, INDP shares have decreased by 5.9% and is now trading at $0.7920.
View the best growth stocks for 2025 here
.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced its quarterly earnings data on Thursday, March, 13th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.03.

Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Indaptus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), General Electric (GE), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
3/13/2025
Today
3/19/2025
Next Earnings (Estimated)
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INDP
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$12.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+969.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.44 per share
Price / Book
0.55

Miscellaneous

Free Float
9,957,000
Market Cap
$11.23 million
Optionable
Not Optionable
Beta
1.60
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:INDP) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners